The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma
- 5 November 2018
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 8 (2) , e1546543
Abstract
Invariant natural killer T (iNKT) cells are a small population of T lymphocytes that expresses an invariant T cell receptor with a unique specificity for glycolipid antigens. Their activation using the glycolipid α-galactosylceramide (α-GalCer) triggers innate and adaptive immune responses. The use of α-GalCer in preclinical models as a single antitumor treatment showed moderate effect, but its efficacy in cancer patients was less effective. In addition, this glycolipid induces long-term iNKT-cell anergy precluding the possibility of retreatment. Recently, the first murine iNKT-cell agonistic antibody, NKT14m, has been developed. Here, we analyzed, for the first time, the antitumor efficacy of NKT14m in a B-cell lymphoma model. In a therapeutic setting, a single dose of NKT14m had a moderate antitumor efficacy that was associated with an increase of IFN-γ producing iNKT cells even after a second dose of the NKT14m antibody. Importantly, the combination of a single dose of NKT14m with cyclophosphamide had a potent antitumor efficacy and long-lasting immunity in vivo. Our findings provide the first evidence of the in vivo antitumor efficacy of NKT14m antibody, showing that, either alone or in combination with chemotherapy, induces an effective antitumor response. These results open new opportunities for iNKT-cell mediated immunotherapy to treat B-cell lymphoma.Keywords
Funding Information
- Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya (AGAUR 2017SGR-1395)
- Instituto de Salud Carlos III (Tercel RD16/0011/0028)
- Instituto de Salud Carlos III (PI15/1383)
This publication has 48 references indexed in Scilit:
- Invariant natural killer T cells: an innate activation scheme linked to diverse effector functionsNature Reviews Immunology, 2013
- Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myelomaBlood, 2013
- NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphomaBlood, 2012
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancerNature Communications, 2011
- Chapter 8 The Role of NKT Cells in Tumor Immunity2008
- Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cellsJournal of Experimental Medicine, 2007
- An NKT-mediated autologous vaccine generates CD4 T-cell–dependent potent antilymphoma immunityBlood, 2007
- Invariant NKT cells sustain specific B cell responses and memoryProceedings of the National Academy of Sciences, 2007
- Therapeutic effect of α‐galactosylceramide‐loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cellsCancer Science, 2005
- Consequences of Cell DeathJournal of Experimental Medicine, 2000